American Competitors

AONC Stock   11.50  0.50  4.17%   
American Oncology Network competes with Transgene, 3-D Matrix, Mayne Pharma, Hansa Biopharma, and Silence Therapeutics; as well as few others. The company conducts business under Health Care Providers & Services sector and is part of Health Care industry. Analyzing American Oncology competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of American Oncology to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out American Oncology Correlation with its peers.

American Oncology vs Medical Facilities Correlation

Average diversification

The correlation between American Oncology Network and MFCSF is 0.18 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding American Oncology Network and MFCSF in the same portfolio, assuming nothing else is changed.
The current year's Return On Tangible Assets is expected to grow to -0.0095. The current year's Return On Capital Employed is expected to grow to -0.08. At present, American Oncology's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Intangibles To Total Assets is expected to grow to 0.03, whereas Total Assets are forecasted to decline to about 312.3 M.
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.5811.5028.94
Details
Intrinsic
Valuation
LowRealHigh
0.479.3026.74
Details

American Oncology Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between American Oncology and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of American and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of American Oncology Network does not affect the price movement of the other competitor.

High positive correlations

MKLNFORPEF
BHCCFORPEF
BHCCFMKLNF
MFCSFTRGNF
DMTRFTRGNF
MFCSFDMTRF
  

High negative correlations

MAYNFDMTRF
MFCSFMAYNF
MAYNFTRGNF
MAYNFEVGRF
SLNCFEVGRF
HNSBFDMTRF

Risk-Adjusted Indicators

There is a big difference between American Stock performing well and American Oncology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze American Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
ORPEF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
EVGRF  1.12  0.40  0.00 (2.89) 0.00 
 0.00 
 37.50 
TRGNF  1.62  0.68  0.00  2.77  0.00 
 0.00 
 61.69 
DMTRF  1.51  0.76  0.00  6.65  0.00 
 0.00 
 27.33 
MAYNF  2.51 (0.44) 0.00  1.23  0.00 
 6.90 
 46.83 
HNSBF  1.09 (0.61) 0.00 (1.05) 0.00 
 0.00 
 36.46 
SLNCF  2.36  0.19  0.00 (0.30) 0.00 
 11.11 
 58.78 
MKLNF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
BHCCF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
MFCSF  1.13  0.16  0.07  0.37  1.22 
 3.88 
 10.55 

American Oncology Competitive Analysis

The better you understand American Oncology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, American Oncology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across American Oncology's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
AONC ORPEF EVGRF TRGNF DMTRF MAYNF HNSBF SLNCF MKLNF BHCCF
 4.17 
 11.50 
American
 0.00 
 14.22 
Orpea
 0.00 
 0 
China
 0.00 
 1.00 
Transgene
 0.00 
 2.37 
3-D
 4.98 
 2.11 
Mayne
 0.00 
 2.91 
Hansa
 6.67 
 1.60 
Silence
 0.00 
 11.73 
MKLNF
 0.00 
 0.37 
Benchmark
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Current Ratio
Net Asset
Profit Margin
EBITDA
Operating Margin
Current Valuation
Price To Book
Retained Earnings
Current Asset
Five Year Return
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Annual Yield
Total Debt
Return On Equity
Z Score
Return On Asset
Number Of Shares Shorted
Book Value Per Share
Current Liabilities
Total Asset
Short Ratio
Debt To Equity
Target Price
Last Dividend Paid
Shares Owned By Institutions
Market Capitalization
Price To Earning
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Cash Per Share
Gross Profit
Daily Balance Of Power
Day Typical Price
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

American Oncology Competition Performance Charts

Five steps to successful analysis of American Oncology Competition

American Oncology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by American Oncology Network in relation to its competition. American Oncology's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of American Oncology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact American Oncology's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to American Oncology Network, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your American Oncology position

In addition to having American Oncology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Broad Sovereign ETFs Thematic Idea Now

Broad Sovereign ETFs
Broad Sovereign ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Sovereign ETFs theme has 14 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Sovereign ETFs Theme or any other thematic opportunities.
View All  Next Launch
When determining whether American Oncology Network offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of American Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of American Oncology Network Stock. Outlined below are crucial reports that will aid in making a well-informed decision on American Oncology Network Stock:
Check out American Oncology Correlation with its peers.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Will Health Care Providers & Services sector continue expanding? Could American diversify its offerings? Factors like these will boost the valuation of American Oncology. If investors know American will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every American Oncology data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(0.89)
Revenue Per Share
128.267
Quarterly Revenue Growth
0.514
Return On Assets
(0.02)
Return On Equity
(0.30)
Understanding American Oncology Network requires distinguishing between market price and book value, where the latter reflects American's accounting equity. The concept of intrinsic value - what American Oncology's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push American Oncology's price substantially above or below its fundamental value.
Understanding that American Oncology's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether American Oncology represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, American Oncology's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.